ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2403

Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
Abstract Number: 2404

Clinical features of Elderly-onset Systemic Lupus Erythematosus
Abstract Number: 2405

Machine Learning in SLE Diagnosis: Performance of the SLE Risk Probability Index Questionnaire in a Multicenter Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: 2406

Machine Learning-Based Artificial Intelligence in Systemic Lupus Erythematosus: A Systematic Review of Outcome Prediction and Patient Stratification
Abstract Number: 2407

Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis
Abstract Number: 2408

Direct Medical Cost Burden of Cutaneous Lupus Erythematosus (CLE): A Comparison with Psoriasis, Atopic Dermatitis, and a General Population
Abstract Number: 2409

Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study
Abstract Number: 2410

Immune Cell/Pathway-Specific Polygenic Risk Scores Reveal Immune Pathway Associations in Childhood-Onset Lupus Nephritis
Abstract Number: 2411

The 2019 EULAR/ACR and 2012 SLICC Classification Criteria for SLE Should Be Applied with Caution as Diagnostic Criteria
Abstract Number: 2412

Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis
Abstract Number: 2413

Hydroxychloroquine and Adverse Cardiovascular Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
Abstract Number: 2414

Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development
Abstract Number: 2415

Evaluating the Readability and Comprehension of Patient Education Materials for Systemic Lupus Erythematosus (SLE) Available Online
Abstract Number: 2416

Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Abstract Number: 2417

Anti-dense fine speckled 70 antibodies in undefined disease, systemic autoimmune rheumatic diseases and controls

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].